CreativeOne Wealth LLC Invests $497,000 in Shockwave Medical, Inc. (NASDAQ:SWAV)

CreativeOne Wealth LLC acquired a new position in Shockwave Medical, Inc. (NASDAQ:SWAV - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,608 shares of the company's stock, valued at approximately $497,000.

Several other large investors have also recently bought and sold shares of SWAV. EverSource Wealth Advisors LLC increased its position in shares of Shockwave Medical by 297.4% in the third quarter. EverSource Wealth Advisors LLC now owns 155 shares of the company's stock valued at $31,000 after buying an additional 116 shares in the last quarter. Asset Management One Co. Ltd. purchased a new position in shares of Shockwave Medical in the fourth quarter valued at $34,000. Quest Partners LLC purchased a new position in shares of Shockwave Medical in the fourth quarter valued at $41,000. Operose Advisors LLC purchased a new stake in Shockwave Medical during the 3rd quarter worth about $49,000. Finally, Covestor Ltd increased its position in Shockwave Medical by 484.9% during the 3rd quarter. Covestor Ltd now owns 427 shares of the company's stock worth $85,000 after purchasing an additional 354 shares in the last quarter. Hedge funds and other institutional investors own 95.35% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Wolfe Research reiterated a "peer perform" rating on shares of Shockwave Medical in a research report on Friday, April 5th. SVB Leerink reissued a "market perform" rating and issued a $335.00 price target (down from $361.00) on shares of Shockwave Medical in a research note on Monday, April 8th. Wells Fargo & Company raised their price target on Shockwave Medical from $200.00 to $210.00 and gave the stock an "equal weight" rating in a research note on Friday, February 16th. Canaccord Genuity Group reissued a "hold" rating and issued a $335.00 price target (up from $263.00) on shares of Shockwave Medical in a research note on Friday, April 5th. Finally, CL King reissued a "neutral" rating on shares of Shockwave Medical in a research note on Monday, April 8th. Ten investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. According to MarketBeat.com, Shockwave Medical presently has an average rating of "Hold" and an average price target of $309.11.

Shockwave Medical Stock Up 0.0 %

Shares of SWAV traded up $0.05 during midday trading on Friday, reaching $334.15. 1,191,361 shares of the stock were exchanged, compared to its average volume of 924,901. The firm has a 50 day simple moving average of $321.44 and a 200-day simple moving average of $249.75. The company has a quick ratio of 12.61, a current ratio of 13.81 and a debt-to-equity ratio of 0.97. Shockwave Medical, Inc. has a 12-month low of $157.00 and a 12-month high of $334.28. The company has a market cap of $12.55 billion, a price-to-earnings ratio of 78.07, a P/E/G ratio of 2.43 and a beta of 0.88.

Shockwave Medical (NASDAQ:SWAV - Get Free Report) last posted its earnings results on Monday, May 6th. The company reported $1.44 EPS for the quarter, topping the consensus estimate of $0.99 by $0.45. Shockwave Medical had a return on equity of 24.79% and a net margin of 20.75%. The business had revenue of $218.80 million during the quarter, compared to the consensus estimate of $207.69 million. During the same quarter last year, the company earned $1.03 EPS. Shockwave Medical's revenue was up 35.8% on a year-over-year basis. Research analysts forecast that Shockwave Medical, Inc. will post 5.05 EPS for the current year.

Insider Activity

In other news, insider Isaac Zacharias sold 4,000 shares of Shockwave Medical stock in a transaction on Tuesday, March 26th. The stock was sold at an average price of $287.67, for a total value of $1,150,680.00. Following the completion of the sale, the insider now directly owns 56,818 shares of the company's stock, valued at approximately $16,344,834.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Isaac Zacharias sold 4,000 shares of Shockwave Medical stock in a transaction on Tuesday, March 26th. The stock was sold at an average price of $287.67, for a total transaction of $1,150,680.00. Following the completion of the sale, the insider now directly owns 56,818 shares of the company's stock, valued at $16,344,834.06. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Frank T. Watkins sold 2,000 shares of Shockwave Medical stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $253.65, for a total value of $507,300.00. Following the sale, the director now directly owns 4,532 shares of the company's stock, valued at $1,149,541.80. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,521 shares of company stock valued at $3,154,736. Company insiders own 3.40% of the company's stock.

Shockwave Medical Profile

Shockwave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels.